Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by NBC Securities Inc.

NBC Securities Inc. boosted its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 97,037.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,313 shares of the company’s stock after purchasing an additional 23,289 shares during the quarter. NBC Securities Inc.’s holdings in Progyny were worth $520,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Voya Investment Management LLC raised its stake in Progyny by 1.4% during the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company’s stock valued at $893,000 after acquiring an additional 701 shares in the last quarter. Signaturefd LLC raised its stake in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. KBC Group NV raised its stake in Progyny by 84.6% during the 4th quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after acquiring an additional 2,140 shares in the last quarter. F M Investments LLC raised its stake in Progyny by 13.0% during the 4th quarter. F M Investments LLC now owns 20,420 shares of the company’s stock valued at $352,000 after acquiring an additional 2,342 shares in the last quarter. Finally, Entropy Technologies LP raised its stake in Progyny by 5.5% during the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company’s stock valued at $826,000 after acquiring an additional 2,499 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on PGNY. Canaccord Genuity Group cut their target price on Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, May 12th. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Monday, March 31st. Finally, Bank of America lifted their target price on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $23.45.

Progyny Stock Performance

PGNY opened at $21.36 on Friday. Progyny, Inc. has a one year low of $13.39 and a one year high of $30.42. The stock’s fifty day moving average is $22.05 and its 200-day moving average is $20.29. The company has a market capitalization of $1.83 billion, a PE ratio of 36.83, a P/E/G ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same period in the prior year, the firm posted $0.17 EPS. The firm’s quarterly revenue was up 16.5% on a year-over-year basis. On average, equities research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.